福元医药：兰索拉唑肠溶胶囊获得药品注册证书

Core Viewpoint - The company has received the drug registration certificate for Lansoprazole enteric-coated capsules, which will enhance its product line and market competitiveness [1] Group 1 - The National Medical Products Administration has issued a drug registration certificate for Lansoprazole enteric-coated capsules in 15mg and 30mg specifications [1] - The drug is considered to have passed the consistency evaluation, indicating its quality and efficacy [1] - The total R&D investment for this drug by the company amounts to RMB 5.8323 million [1]